• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    4/17/23 9:06:18 AM ET
    $ATIP
    $BTCY
    $CFRX
    $CNSP
    Hospital/Nursing Management
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ATIP alert in real time by email

    Gainers

    • ContraFect (NASDAQ:CFRX) stock moved upwards by 157.8% to $2.32 during Monday's pre-market session. The market value of their outstanding shares is at $3.6 million.
    • Satsuma Pharma (NASDAQ:STSA) stock increased by 122.9% to $1.46. The company's market cap stands at $48.4 million.
    • Prometheus Biosciences (NASDAQ:RXDX) stock increased by 69.79% to $193.59. The company's market cap stands at $9.2 billion.
    • CNS Pharma (NASDAQ:CNSP) stock increased by 44.25% to $3.39. The market value of their outstanding shares is at $7.5 million.
    • Kiromic BioPharma (NASDAQ:KRBP) shares moved upwards by 26.12% to $5.89. The company's market cap stands at $4.0 million.
    • Biotricity (NASDAQ:BTCY) stock rose 24.59% to $0.66. The company's market cap stands at $34.6 million.

    Losers

    • Pear Therapeutics (NASDAQ:PEAR) shares decreased by 26.7% to $0.05 during Monday's pre-market session. The market value of their outstanding shares is at $7.5 million.
    • Petros Pharma (NASDAQ:PTPI) stock decreased by 18.96% to $3.72. The market value of their outstanding shares is at $7.7 million.
    • ATI Physical Therapy (NYSE:ATIP) stock declined by 16.93% to $0.24. The market value of their outstanding shares is at $49.7 million.
    • Regulus Therapeutics (NASDAQ:RGLS) stock declined by 15.97% to $1.0. The market value of their outstanding shares is at $16.8 million.
    • Predictive Oncology (NASDAQ:POAI) stock fell 15.82% to $0.32. The market value of their outstanding shares is at $25.4 million.
    • Silence Therapeutics (NASDAQ:SLN) stock fell 12.26% to $5.44. The company's market cap stands at $195.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATIP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATIP
    $BTCY
    $CFRX
    $CNSP

    CompanyDatePrice TargetRatingAnalyst
    Regulus Therapeutics Inc.
    $RGLS
    3/27/2025$3.00 → $6.00Equal Weight → Overweight
    Wells Fargo
    Silence Therapeutics Plc
    $SLN
    2/11/2025$6.00Sell
    Goldman
    Silence Therapeutics Plc
    $SLN
    12/2/2024Outperform
    BMO Capital Markets
    Silence Therapeutics Plc
    $SLN
    9/3/2024$40.00Buy
    Jefferies
    Predictive Oncology Inc.
    $POAI
    8/19/2024$3.00Buy
    H.C. Wainwright
    Regulus Therapeutics Inc.
    $RGLS
    8/2/2024$7.00Outperform
    Oppenheimer
    Regulus Therapeutics Inc.
    $RGLS
    3/18/2024$6.00Outperform
    Leerink Partners
    Silence Therapeutics Plc
    $SLN
    1/31/2024$67.00Outperform
    BMO Capital Markets
    More analyst ratings

    $ATIP
    $BTCY
    $CFRX
    $CNSP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA

    REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "The need for proactive chronic care manag

    2/11/26 4:00:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th

    Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity's Founder and CEO, Dr. Waqa

    2/5/26 4:15:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Silence Therapeutics Announces Leadership Changes

    Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the Company's President, Chief Executive Officer and Board member since 2022, agreed by mutual consent to end his employment with the Company effective 14 December 2025. Iain Ross, Chairman of the Silence Board, will lead the Company with immediate effect on an interim basis. Additionally, James Ede Golightly, a former Silence Non-Executive Director, has been re-appointed to the Company's Board of Directors. An additional appointment of an US-based Board member is anticipated in due

    12/15/25 8:13:00 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATIP
    $BTCY
    $CFRX
    $CNSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & Head of R & D Klassen Preston bought $95,852 worth of shares (12,000 units at $7.99), increasing direct ownership by 33% to 48,055 units (SEC Form 4)

    4 - Regulus Therapeutics Inc. (0001505512) (Issuer)

    6/4/25 5:00:15 PM ET
    $RGLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Hagan Joseph P bought $54,260 worth of shares (50,000 units at $1.09), increasing direct ownership by 24% to 260,808 units (SEC Form 4)

    4 - Regulus Therapeutics Inc. (0001505512) (Issuer)

    1/31/25 5:00:10 PM ET
    $RGLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baltimore David bought $20,787 worth of shares (19,610 units at $1.06), increasing direct ownership by 766% to 22,169 units (SEC Form 4)

    4 - Regulus Therapeutics Inc. (0001505512) (Issuer)

    1/31/25 5:00:06 PM ET
    $RGLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATIP
    $BTCY
    $CFRX
    $CNSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Griffiths Richard Ian

    4 - Silence Therapeutics plc (0001479615) (Issuer)

    2/13/26 6:02:01 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Boctor Fady was granted 500,000 shares, increasing direct ownership by 2,502% to 519,986 units (SEC Form 4)

    4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

    1/6/26 5:30:07 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ede-Golightly James

    4 - Silence Therapeutics plc (0001479615) (Issuer)

    1/6/26 4:15:24 PM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATIP
    $BTCY
    $CFRX
    $CNSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Regulus Therapeutics upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Regulus Therapeutics from Equal Weight to Overweight and set a new price target of $6.00 from $3.00 previously

    3/27/25 1:44:29 PM ET
    $RGLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Silence Therapeutics with a new price target

    Goldman initiated coverage of Silence Therapeutics with a rating of Sell and set a new price target of $6.00

    2/11/25 7:12:20 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BMO Capital Markets reiterated coverage on Silence Therapeutics

    BMO Capital Markets reiterated coverage of Silence Therapeutics with a rating of Outperform

    12/2/24 10:09:42 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATIP
    $BTCY
    $CFRX
    $CNSP
    SEC Filings

    View All

    CNS Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    3/2/26 5:00:26 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by CNS Pharmaceuticals Inc.

    S-8 - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    2/27/26 5:22:40 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biotricity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BIOTRICITY INC. (0001630113) (Filer)

    2/18/26 5:30:35 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $ATIP
    $BTCY
    $CFRX
    $CNSP
    Leadership Updates

    Live Leadership Updates

    View All

    Silence Therapeutics Announces Leadership Changes

    Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the Company's President, Chief Executive Officer and Board member since 2022, agreed by mutual consent to end his employment with the Company effective 14 December 2025. Iain Ross, Chairman of the Silence Board, will lead the Company with immediate effect on an interim basis. Additionally, James Ede Golightly, a former Silence Non-Executive Director, has been re-appointed to the Company's Board of Directors. An additional appointment of an US-based Board member is anticipated in due

    12/15/25 8:13:00 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy

    Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, respectively PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and the first Strategic Compute Reserve leveraging the Aethir ecosystem to democratize access to AI infrastructure, today announced additions to its leadership team and Board of Directors in support of the Company's new digital asset treasury strategy focused on the Aethir (ATH) token. The Company announced today that Shawn Matthews, CEO of

    10/14/25 8:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Silence Therapeutics Welcomes Tim McInerney to Board of Directors

    Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company's Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting ("AGM") in June 2025. "We are thrilled to welcome Tim to the Silence Board," said Iain Ross, Chairman of the Silence Board. "Tim is a seasoned executive and board memb

    5/6/25 7:45:00 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATIP
    $BTCY
    $CFRX
    $CNSP
    Financials

    Live finance-specific insights

    View All

    Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA

    REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "The need for proactive chronic care manag

    2/11/26 4:00:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th

    Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity's Founder and CEO, Dr. Waqa

    2/5/26 4:15:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy

    PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today reported financial and operating results for the quarter ended September 30, 2025, and provided a corporate update. Q3 2025 and Recent Highlights: Announced the initiation of a digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem, supported by two private placements pursuant to which the Company received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of lo

    11/14/25 5:12:46 PM ET
    $POAI
    Industrial Specialties
    Health Care

    $ATIP
    $BTCY
    $CFRX
    $CNSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/17/24 5:51:04 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/2/24 4:57:34 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    11/25/24 8:12:55 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care